GU Cancer Clinical Trials

DISCLAIMER: All content found on cua.org is provided for information and education purposes. The medical information and clinical trials information is not intended to substitute for the advice of a physician, nor is it intended to provide legal advice. You should always consult your doctor for specific information on personal health matters, or other relevant professionals to ensure that your own circumstances are considered.

The CUA is not responsible in any manner for direct, indirect, special or consequential damages caused and/or arising from your use of cua.org.

Subspecialty
Bladder | AB, ON | Recruiting
RADIANT
Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC (RADIANT)
Dr. Michael Ong
Start Date: January 29, 2021

NCT #: NCT04543110

SPONSOR: Ottawa Hospital Research Institute in collaboration with: Cross Cancer Institute, Hamilton Health Sciences Corporation, London Health Sciences Centre, Ontario Institute for Cancer Research, AstraZeneca, Ozmosis Research Inc.

INFO: https://clinicaltrials.gov/ct2/show/NCT04543110?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=10

CONTACT: 613-737-7700 ext 70179

OTHER CANADIAN CENTRES:

1. Cross Cancer Institute (Edmonton): 780-432-8248                                                            
2. Ottawa Hospital Cancer Centre (OHRI): 613-737-7700 ext 70179                              
3. Juravinski Cancer Centre (Hamilton): lalania@HHSC.CA                                                   
4. London Health Sciences Centres (London): 519-685-8600
 

Prostate | BC, ON, QC | Recruiting
PATRON
PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer (PATRON)
Cynthia Menard
Start Date: January 6, 2021

NCT #: NCT04557501

INFO: https://clinicaltrials.gov/ct2/show/NCT04557501

CONTACT:  514-890-8254

Prostate | AB, BC, NS, ON, QC | Active, not recruiting
PROpel
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
Dr. Fred Saad
Start Date: January 6, 2021
Prostate | ON | Recruiting
SHARP
SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer
Dr. Mark Corkum
Start Date: December 23, 2020

NCT #: NCT04861415

SPONSOR: Sunnybrook Health Sciences Centre

INFO: https://clinicaltrials.gov/ct2/show/NCT04861415

CONTACT:  416-480-6100 ext 6165

Renal | ON, QC | Recruiting
MK-3475-03B
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Start Date: December 17, 2020

NCT #: NCT04626518

SPONSOR: Merck Sharp & Dohme LLC

INFO:  https://clinicaltrials.gov/ct2/show/NCT04626518?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=16

CONTACT:

Princess Margaret Cancer Centre (Toronto): 416-946-4501 x 5606          

Jewish General Hospital (Montreal): 514-340-8222 x 24572

OTHER CANADIAN CENTRES:

Princess Margaret Cancer Centre (Toronto)                                        

Jewish General Hospital (Montreal)                                              

Renal | ON, QC | Recruiting
MK-3475-03A
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Start Date: December 16, 2020

NCT #: NCT04626479

SPONSOR: Merck Sharp & Dohme LLC

INFO:  https://clinicaltrials.gov/ct2/show/NCT04626518?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=16

CONTACT: 

Princess Margaret Cancer Centre (Toronto): 416-946-4501 x 5606          

Jewish General Hospital (Montreal): 514-340-8222 x 24572

OTHER CANADIAN CENTRES:

Princess Margaret Cancer Centre (Toronto), Jewish General Hospital (Montreal)

Prostate | SK | Recruiting
PSMA-01
68Ga-PSMA PET/CT in Prostate Cancer
Dr. Rajan Rakheja
Start Date: December 9, 2020

NCT#:  NCT04684628

SPONSOR: University of Saskatchewan

INFO:  https://clinicaltrials.gov/ct2/show/NCT04684628

CONTACT:  306-655-3351

Bladder | ON, QC | Recruiting
SunRISe-2
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)
Start Date: December 7, 2020

NCT #: NCT04658862

SPONSOR: Janssen Research & Development, LLC

INFO: https://clinicaltrials.gov/ct2/show/NCT04658862?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=6 

CONTACT:  844-434-4210

OTHER CANADIAN CENTRES:

1. The Male/Female Health and Research Centre (Barrie)                                  

2. University of Toronto:                                                                                                          

3. McGill University Health Centre (Montreal):                                                                  

4. CHU de Québec -L'Hôtel-Dieu de Québec (Québec City)                                                          

5. Centre Hospitalier Universitaire de Sherbrooke

Prostate | BC, QC | Recruiting
PR21
A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease
Dr. Francois Benard (BCCA), Dr. Kim Chi (BCCA), Dr. Fred Saad (CHUM)
Start Date: December 1, 2020

NCT #: NCT04663997

INFO: https://www.clinicaltrials.gov/ct2/show/NCT04663997

CONTACT:

(604) 675-8206

(604) 877-6000 x 2746

(514) 890-8000 x 27466

 

Renal | ON | Recruiting
PDXovo
Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors (PDXovo)
Dr. Georg Bjarnason (Sunnybrook Health Sciences Centre)
Start Date: December 1, 2020

NCT #: NCT04602702

SPONSOR: Sunnybrook Health Sciences Centre

INFO: https://clinicaltrials.gov/ct2/show/NCT04602702?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2

CONTACT: 416-480-6100 x 5748

OTHER CANADIAN CENTRES:  Odette Cancer Centre (Toronto)

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy